STERIS plc Form 10-K Summary
Business context and reporting period
STERIS provides infection prevention, sterilization, surgical, healthcare, life sciences, and related services through its Healthcare, Applied Sterilization Technologies (AST), and Life Sciences segments. The filing covers the fiscal year ended March 31, 2024. The requested 2023 Q4 period corresponds to the quarter ended March 31, 2024, which is the fourth quarter of fiscal 2024.
Dental was reclassified to discontinued operations after meeting held-for-sale criteria before year-end. Historical results were retrospectively adjusted for comparability. The planned Dental sale was announced April 11, 2024, for $787.5 million of cash consideration, subject to customary adjustments, plus up to $12.5 million of contingent consideration.
Financial performance and key metrics
| Metric | Fiscal 2024 | Fiscal 2023 | Change |
|---|---|---|---|
| Continuing-operations revenue | $5,138.7 million | $4,536.3 million | 13.3% increase |
| Gross profit | $2,218.2 million | $1,980.7 million | 12.0% increase |
| Gross margin | 43.2% | 43.7% | 50 basis-point decline |
| Income from operations | $836.1 million | $791.1 million | 5.7% increase |
| Income from continuing operations | $553.3 million | $556.2 million | 0.5% decrease |
| Diluted EPS from continuing operations | $5.55 | $5.56 | Essentially flat |
| Net cash from operating activities | $973.3 million | $756.9 million | 28.6% increase |
| Free cash flow | $620.3 million | $409.6 million | 51.5% increase |
| Total debt at year-end | $3,206.1 million | $3,078.7 million | $127.4 million increase |
Fiscal 2024 total net income attributable to shareholders was $378.2 million, or $3.81 diluted EPS, including a $173.2 million loss from discontinued operations. Continuing-operations results were substantially stronger than reported consolidated net income suggests.
Fourth-quarter fiscal 2024 revenue was $1,419.4 million, gross profit was $582.9 million, and gross margin was 41.1%. Income from continuing operations was $153.3 million. A $154.3 million loss from discontinued operations produced a consolidated net loss attributable to shareholders of $1.4 million, or $0.01 per diluted share, for the quarter.
- Revenue by type: service revenue increased 9.3% to $2,374.7 million; consumables increased 16.2% to $1,502.4 million; and capital equipment increased 17.9% to $1,261.6 million.
- Segment revenue growth was 17.1% for Healthcare, 4.3% for AST, and 6.5% for Life Sciences.
- Healthcare operating margin improved to 24.1% from 22.9%; AST margin declined to 46.1% from 46.9%; and Life Sciences margin declined to 38.7% from 39.2%.
- Cash and cash equivalents were $207.0 million at March 31, 2024. The revolving credit facility had $484.5 million outstanding and approximately $754.0 million of unused availability, net of letters of credit.
- Debt-to-total capital was 33.7%, compared with 33.6% in the prior year. STERIS reported compliance with all financial covenants.
- Capital expenditures were $360.3 million. Cash dividends paid were $200.6 million, or $2.03 per share; the quarterly dividend was increased to $0.52 per share.
- Backlog declined to $425.2 million from $599.6 million, primarily because supply-chain constraints eased and shipments increased.
Material changes versus the prior comparable period
- STERIS acquired surgical instrumentation, laparoscopic instrumentation, and sterilization-container assets from Becton, Dickinson and Company for $539.8 million on August 2, 2023. The acquisition was financed with borrowings under the existing credit facility and contributed to Healthcare growth.
- Gross margin declined because of inflation in materials and labor, productivity pressures, restructuring charges, adjustments, and currency effects, partly offset by pricing and mix.
- Interest expense increased to $144.4 million from $108.0 million, primarily because of higher interest rates and increased floating-rate debt.
- Fiscal 2024 included $44.4 million of restructuring costs, including $26.1 million in restructuring expense and $18.3 million in cost of revenues. The plan includes a strategic shift in European Healthcare surgical operations, product rationalizations, facility consolidations, and fewer than 300 planned position eliminations.
- Management expects approximately $55.3 million of additional restructuring costs and approximately $25.0 million of annual operating-income improvement, with most benefits expected in fiscal 2026 and later.
- Dental generated a $173.2 million net loss from discontinued operations in fiscal 2024, including a $206.4 million pre-tax loss associated with classification as held for sale. Proceeds from the planned sale are intended to repay debt.
- Fiscal 2024 operating cash flow benefited from stronger operating activity and lower working-capital cash usage. Investing cash outflows increased mainly because of the BD acquisition.
Guidance, outlook, risks, contingencies, and unusual items
Management did not provide quantified fiscal 2025 revenue, earnings, or cash-flow guidance in the supplied filing text. STERIS expects to manage costs, pursue internal product and service development, invest in capacity, and supplement organic growth with potential acquisitions. Management expects inflation to continue in fiscal 2025, but at a lower level than in fiscal 2023 and fiscal 2024.
- Key operating risks include healthcare and pharmaceutical demand, customer pricing pressure, inflation, labor costs, supply-chain disruptions, limited sources for ethylene oxide and cobalt-60, and foreign-currency volatility.
- AST faces regulatory and litigation exposure related to ethylene oxide sterilization, including potential facility restrictions, higher compliance costs, personal-injury claims, and possible limits on the use of ethylene oxide.
- STERIS stopped purchasing cobalt-60 from its Russian supplier. Management does not expect the resulting risk to be material to AST, but a prolonged disruption could reduce gamma-processing capacity or increase costs.
- Geopolitical conflicts, sanctions, tariffs, interest rates, cybersecurity threats, and future public-health crises could affect operations, demand, costs, and liquidity.
- Tax uncertainty includes an IRS dispute concerning deemed dividend inclusions and withholding tax for 2018. The IRS adjustments would result in an estimated cumulative tax liability of approximately $50 million; STERIS is contesting the matter and has not recorded a reserve.
- The Company reported no material cybersecurity incident during fiscal 2024, no FDA warning letters, seizures, or consent decrees, and no Class I recalls in fiscal 2022 through fiscal 2024.
- Goodwill was $4.1 billion and net intangible assets were $2.1 billion at year-end. Future impairment charges remain a risk, particularly if operating or macroeconomic conditions deteriorate.
- The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The fiscal 2024 audit did not include controls of acquired entities representing approximately 5.0% of total assets and 2.0% of revenue.
Most important facts an investor should verify
- Completion of the Dental divestiture, final proceeds, contingent consideration, and the amount of debt repaid with sale proceeds.
- Actual fiscal 2025 revenue, margin, EPS, operating cash-flow, and restructuring-cost performance versus management’s qualitative outlook.
- Progress toward the planned $25.0 million annual operating-income benefit and the timing of the remaining approximately $55.3 million of restructuring costs.
- Debt maturities, refinancing requirements, floating-rate exposure, and the impact of interest rates on cash flow. Fiscal 2025 debt maturities were $165.9 million, followed by $662.0 million in fiscal 2026.
- Whether Healthcare growth and pricing can offset inflation, labor costs, productivity issues, and weaker AST volume.
- Resolution of the approximately $50 million IRS tax dispute and the effect of Pillar Two, other tax-law changes, or tax-treaty challenges on the effective tax rate.
- Potential liabilities from ethylene oxide litigation, regulatory actions, environmental matters, product claims, and other contingencies.
- Whether the BD purchase-price allocation remains preliminary and whether customer-relationship valuation, goodwill, or integration assumptions change materially.